Based on these premises, we analyzed the outcomes of a large cohort of 513 Italian patients who received on‐label CPX‐351 treatment since its approval, in order to evaluate the optimal duration of CPX‐351 treatment, the best timing for allo‐HSCT, and the efficacy of CPX‐351 on rare secondary AML subtypes such as those with NPM1 or FLT3‐ITD mutations. The gene discussed is NPM1; the disease is acute myeloid leukemia.